16 May Fecal Microbiota Transplantation is Promising Option for Ulcerative Colitis Treatment

Posted at 15:09h in Author Interviews, Gastrointestinal Disease, Microbiome, Transplantation by

MedicalResearch.com Interview with:
Dr. Sudarshan Paramsothy
University of New South Wales
Australia

MedicalResearch.com: What is the background for this study? What are the main findings?

Dr. Paramsothy: This study was conducted as there is strong evidence that the gastrointestinal microbiota play a critical role in the underlying pathogenesis of inflammatory bowel disease (IBD), but treatments to date primarily are focused on controlling the associated immune response. Attempts at therapeutic microbial manipulation in ulcerative colitis (UC) to date (antibiotics, probiotics, prebiotics) have not been as impressive as one might expect. We felt intensive fecal microbiota transplantation (FMT) may be more successful than these other methods, as it involves transplanting the entire gastrointestinal microbiota from a health individual, and thus more likely to correct any underlying microbial disturbance or dysbiosis in the recipient UC patient.

Our study found that significantly more active ulcerative colitis patients treated with intensive FMT than placebo (27% vs 8%) achieved the trial primary composite endpoint of both

  • clinical remission induction (ie resolution of symptoms) and
  • endoscopic remission or response (ie either healing or significant improvement of the bowel lining)

MedicalResearch.com: What should readers take away from your report?

Dr. Paramsothy: Readers should take away from this study that  fecal microbiota transplantation is a very promising therapeutic option for ulcerative colitis patients though ongoing studies are warranted.

MedicalResearch.com: What recommendations do you have for future research as a result of this study?

Dr. Paramsothy: Future research should focus on

  • characterizing the microbiological changes associated with Fecal Microbiota Transplantation is Promising Option for  Ulcerative Colitis Treatment and how these relate to outcomes and selection of both donors and patients
  • the role of FMT in maintenance of remission in UC (this study looked at only induction of remission)
  • longer term outcomes in terms of both efficacy and safety

MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.

Citation: Abstract presented at the The 11th Congress of ECCO was held on March 16-19, 2016 , Amsterdam

[wysija_form id=”5″] 

 

OP017 Multi-donor intense faecal microbiota transplantation is an effective treatment for resistant ulcerative colitis: a randomised placebo-controlled trial

  1. Paramsothy*1, M. Kamm2, 3, A. Walsh4, J. van den Bogaerde5, D. Samuel6, R. Leong6, S. Connor7, W. Ng7, R. Paramsothy7, N. Kaakoush8, H. Mitchell8, W. Xuan9, E. Lin10, T. Borody10

1University of New South Wales, St Vincent’s Clinical School, Sydney, Australia, 2St Vincent’s Hospital, Melbourne, Australia,3Imperial College London, London, United Kingdom, 4St Vincent’s Hospital, Sydney, Australia, 5Nambour General Hospital, Nambour, Australia, 6Bankstown-Lidcombe Hospital, Sydney, Australia, 7Liverpool Hopsital, Sydney, Australia, 8University of New South Wales, School of Biotechnology & Biomolecular Sciences, Sydney, Australia, 9Ingham Institute, Sydney, Australia,10Centre for Digestive Diseases, Sydney, Australia

Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.

More Medical Research Interviews on MedicalResearch.com

 

 

 

Last Updated on June 2, 2016 by Marie Benz MD FAAD

359
Tags:
,